Category Archives: Ventricular Remodeling

After careful consideration, the Endocrine Society canceled its annual meeting (ENDO 2020), which was set to take place in San Francisco, California, from March 28 to 31, 2020, because of concerns regarding coronavirus disease 2019 (COVID-19). Research findings that were scheduled to be presented at the meeting have been published in a supplemental issue of the Journal of the Endocrine Society. The society is hosting ENDO Online, a complimentary virtual event featuring on-demand and live programming, from June 8 to 22, 2020, to provide a platform for continued learning and research exhibition. Continue reading →

A set of guidelines regarding the use of multimodality cardiovascular (CV) imaging in young adult competitive athletes, focusing on the distinction between exercise-induced cardiac remodeling (EICR) and cardiac pathology, was formulated by an expert writing group and published in the Journal of the American Society of Echocardiography. This report was endorsed by the American Society of Echocardiography, in conjunction with the Society of CV Computed Tomography (CT) and the Society for CV Magnetic Resonance (CMR). Young competitive athletes with unrecognized CV disease (CVD) who undergo strenuous exercise may be at increased risk for serious adverse events, including sudden cardiac death. Continue reading →

As per a report published by National Heart, Lung, and Blood Institute (NHLBI), heart failure incidences continue to rise in the United States with approximately 825,000 new cases diagnosed in 2013. As per NHLBI, 5.1 million Americans over the age of 20 have heart failures and this number is projected to increase by 46% to reach 8 million by 2030. Cardiac restoration systems are usually used after a coronary artery bypass grafting and may precede or be followed by mitral valve repair or other procedures such as endocardectomy and cryoablation Continue reading →

The term cardiac remodelling (REM) is used to define changes that produce geometrical rearrangement of the normal structures of the heart, together with complex biological and molecular alterations. REM affects the heart at the level of the cardiomyocyte, the blood vessels and the extracellular matrix. Continue reading →

Adverse ventricular remodeling after myocardial infarction (MI) is a process of regional and global structural and functional changes in the heart as a consequence of loss of viable myocardium, exuberant inflammatory response, increased wall stress in the border zone and remote myocardium, and neurohormonal activation (Figure 1). Continue reading →

BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that it has been named by FierceMedTech as one of the "Fierce 15" for 2019, designating it as one of the most promising private medtech companies in the industry. The company offers Less Invasive Ventricular Enhancement, or the LIVE Therapy, which uses the Revivent TC Transcatheter Ventricular Enhancement System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently. Continue reading →

OBJECTIVE: This study was an investigation of the severity of inflammation (SOI) in aspirated material and thrombus age to examine any association with pre-discharge and long-term left ventricular (LV) function after ST-elevationmyocardial infarction(STEMI). The study group comprised 25 patients with STEMI from whom an occlusive thrombus was aspirated from the infarct-related artery with a 7-F catheter. The SOI in the aspirate was determined according to the mean leukocyte count in 5 high-power magnification fields and graded as mild in the presence of 100 leukocytes per field or significant if there were > 100 leukocytes per field Continue reading →

REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failure BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC Transcatheter Ventricular Enhancement System as co-principal investigator. Continue reading →

KIRKLAND, Wash., Feb. Continue reading →

Coronary microvascular dysfunction was found to be associated with an increased risk for cardiovascular events and cardiac dysfunction in patients with chronic kidney disease, according to a study published in Circulation. In this longitudinal study, 352 patients without overt coronary, valvular, or end-organ disease, who underwent cardiac stress positron emission tomography (PET), echocardiogram, and renal function assessment at Brigham and Womens Hospital in Boston, Massachusetts, between 2006 and 2016 were enrolled Continue reading →